Antiarrhythmic agent-4
Antiarrhythmic agent-4 is an orally active cardiac ion channel modulator. Antiarrhythmic agent-4 selectively inhibits pathological late sodium current of the cardiac NaV1.5 channel (IC50 = 2.5 μM) while blocking the hERG (IKr) channel (IC50 = 1.5 μM). Antiarrhythmic agent-4 reduces intracellular sodium/calcium overload, prolongs the cardiac action potential, and avoids conduction block and negative inotropic effects. Antiarrhythmic agent-4 exhibits antiarrhythmic efficacy in an isoproterenol-induced atrial fibrillation model in isolated rabbit hearts and improves survival and cardiac function in a Doxorubicin (HY-15142A)-induced heart failure mouse model. Antiarrhythmic agent-4 can be used for research on atrial fibrillation and heart failure.
For research use only. We do not sell to patients.
- Formula: C19H21F3N2O2
- Molecular Weight:366.38
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
IKr |
Nav1.5 2.5 μM (IC50) |
Nav1.2 52.3 μM (IC50) |
Nav1.6 39.5 μM (IC50) |
In Vitro
Antiarrhythmic agent-4 (Compound 8b) (10 μM) is a selective inhibitor of late NaV1.5 in HEK293T cells with an IC50 of 2.5 μM, and a potent inhibitor of hERG channels in CHO cells with an IC50 of 1.5 μM[1].
Antiarrhythmic agent-4 exhibits high selectivity for cardiac late INa over non-cardiac NaV1.X subtypes, with IC50 values exceeding 100 μM for NaV1.1, NaV1.3, NaV1.4, and NaV1.7, and moderate inhibitory activity against NaV1.2 and NaV1.6[1].
Antiarrhythmic agent-4 exhibits negligible inhibitory effect on CaV1.2 channels, with an IC50 of 287.9 μM, suggesting a low risk of negative inotropic effects[1].
Antiarrhythmic agent-4 is predicted to bind well to the central pore of the NaV1.5 channel with a docking score of -9.769, forming key hydrogen bonds and π-π stacking interactions; it also exhibits an excellent binding score of -9.757 in the central pore region of the NaV1.6 channel[1].
Antiarrhythmic agent-4 exhibits dose-dependent anti-atrial fibrillation activity in the ISO-treated isolated rabbit heart model[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Parmacokinetics
| Species | Dose | Route | C0 | T1/2 | AUClast | AUCinf | CL | Vss | Cmax | Tmax | F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mice[1] | 1 mg/kg | i.v. | 220 ng/mL | 5.49 h | 918 ng·h/mL | 958 ng·h/mL | 18.1 mL/min/kg | 7.38 L/kg | / | / | / |
| Mice[1] | 3 mg/kg | i.p. | / | 4.80 h | 2633 ng·h/mL | 2708 ng·h/mL | / | / | 437 ng/mL | 0.417 h | 94.2 % |
| Mice[1] | 3 mg/kg | p.o. | / | 5.02 h | 3046 ng·h/mL | 3156 ng·h/mL | / | / | 386 ng/mL | 0.667 h | 110.0 % |
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6N (male, eight-week-old, injection of Doxorubicin (HY-15142A) (2.15 mg/kg) on days 1, 3, 4, 7, 10, 13, and 15)
[1] -
Dosage:5, 10, 30 mg/kg
-
Administration:i.p.; daily; 16 days
-
Result:Suppressed Doxorubicin-induced mortality and attenuated body weight decline over the 21-day observation period.
Improved stroke volume (SV), ejection fraction (EF), and fractional shortening (FS) to an extent comparable to 50 mg/kg Ranolazine (HY-B0280) at 30 mg/kg.
Was as effective as 50 mg/kg Ranolazine in mitigating the decline in SV, EF, and FS at 10 mg/kg.
Still significantly improved SV and decreased mortality and severe weight loss at 5 mg/kg.
Chemical Information
-
Molecular Weight 366.38
-
Formula C19H21F3N2O2
-
SMILES
NC([C@H](CC)NCCOC1=CC=C(C2=CC=CC(C(F)(F)F)=C2)C=C1)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Cardiac voltage-sensitive optical mapping
Cardiac voltage-sensitive optical mapping records changes in transmembrane potential from cardiac tissue by staining the preparation with a voltage-sensitive dye and imaging fluorescence changes during electrical activation; the resulting optical action potentials can be used to map activation time, action potential duration, conduction velocity, wavefront propagation, and arrhythmia dynamics. The optical signal represents a relative fluorescence change from a tissue volume rather than a single-cell intracellular recording, so spatial resolution, sampling rate, voltage resolution, optical magnification, light penetration, and motion control must be considered together when interpreting optical action potentials.
-
Neuronal voltage-sensitive dye imaging
Neuronal voltage-sensitive dye imaging detects membrane-potential-dependent optical changes from dyes associated with neuronal membranes, enabling optical recording of electrical activity from single neurons, dendrites, axons, spines, or neuronal populations in brain slices and cultured neurons. VSD signals are typically reported as fractional fluorescence or absorbance changes over baseline, such as ΔF/F or ΔI/I, and published protocols use high-speed cameras or photodiode arrays because neuronal voltage signals occur on millisecond time scales. Fast VSD imaging can be applied at two common scales: bulk staining of brain slices to measure circuit-level spatiotemporal activity, and single-cell loading or biolistic delivery to record membrane-potential transients from individual neuronal compartments. Optical signals should be interpreted as membrane-potential-related readouts, and validation by simultaneous electrophysiology or pharmacological controls is recommended when the experimen
-
Acute brain-slice whole-cell patch-clamp recording
Acute brain-slice whole-cell patch-clamp recording measures membrane voltage or ionic current from visually targeted cells in living brain slices; after giga-seal formation, the membrane under the pipette is ruptured to provide low-resistance electrical access to the cell interior, enabling current-clamp analysis of excitability and voltage-clamp analysis of synaptic or membrane currents. Acute slices preserve local tissue architecture better than dissociated preparations and allow visually guided recording from defined brain regions or fluorescently labeled cells; however, whole-cell access also permits exchange between pipette solution and cytoplasm, so intracellular dialysis must be considered when interpreting signaling-dependent phenomena.
-
Two-electrode voltage clamp in Xenopus oocytes
Two-electrode voltage clamp measures whole-oocyte membrane current from Xenopus oocytes expressing exogenous ion channels, receptors, or transporters; one intracellular microelectrode senses membrane voltage, and the second injects current so the amplifier can hold the membrane at command voltages while recording the compensating current as the functional readout. The method is suited to Xenopus oocytes because their large size supports microinjection and intracellular electrode impalement, but the large membrane area can limit voltage-clamp speed and accuracy, especially for large or fast currents.
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
-
How to Choose the Right Model Animal
Choosing the right model animal is a validity-driven decision in which the species, strain, sex, age, genetic background, disease-induction method, outcome measures, and welfare burden must match the scientific question rather than laboratory tradition or convenience. A model should be selected by judging face validity, construct validity, and predictive validity: whether it resembles the human phenotype, whether it reproduces relevant mechanisms, and whether results are likely to predict human biology or treatment response. Animal studies often fail to translate because of species differences, weak disease resemblance, poor experimental design, inadequate reporting, publication bias, and underuse of randomization, blinding, and sample-size justification. Unresolved questions include how to rank competing models objectively, how much human-disease complexity must be reproduced for a given objective, and when non-animal systems such as organoids, ex vivo tissue, or computational models
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)